Stephens Inc Amgen Inc Transaction History

Stephens Inc

$6.77 Billion
Q3 2024

A detailed history of Stephens Inc transactions in Amgen Inc stock. As of the latest transaction made, Stephens Inc holds 52,732 shares of AMGN stock, worth $17 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares

52,732

Previous 54,482 3.21%

Holding current value

$17 Million

Previous $17 Million 0.19%

% of portfolio

0.25%

Previous 0.27%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	SELL	$309.38 - $337.38 $541,415 - $590,415	-1,750 Reduced 3.21%	52,732 $17 Million
Q2 2024 Aug 06, 2024	BUY	$262.75 - $319.31 $696,287 - $846,171	2,650 Added 5.11%	54,482 $17 Million
Q1 2024 May 15, 2024	BUY	$268.87 - $324.56 $485,848 - $586,479	1,807 Added 3.61%	51,832 $14.7 Million
Q4 2023 Feb 13, 2024	BUY	$255.7 - $288.46 $70,317 - $79,326	275 Added 0.55%	50,025 $14.4 Million
Q3 2023 Nov 14, 2023	SELL	$218.65 - $271.46 $490,213 - $608,613	-2,242 Reduced 4.31%	49,750 $13.4 Million
Q2 2023 Aug 14, 2023	BUY	$214.27 - $253.37 $2.37 Million - $2.81 Million	11,076 Added 27.07%	51,992 $11.5 Million
Q1 2023 May 15, 2023	BUY	$225.79 - $275.2 $864,098 - $1.05 Million	3,827 Added 10.32%	40,916 $9.89 Million
Q4 2022 Jan 25, 2023	SELL	$229.03 - $291.01 $1.29 Million - $1.64 Million	-5,632 Reduced 13.18%	37,089 $9.74 Million
Q3 2022 Nov 02, 2022	BUY	$224.46 - $253.15 $168,793 - $190,368	752 Added 1.79%	42,721 $9.63 Million
Q2 2022 Aug 03, 2022	SELL	$230.71 - $256.74 $260,240 - $289,602	-1,128 Reduced 2.62%	41,969 $10.2 Million
Q1 2022 May 04, 2022	SELL	$219.27 - $242.57 $278,692 - $308,306	-1,271 Reduced 2.86%	43,097 $10.4 Million
Q4 2021 Mar 07, 2022	BUY	$198.88 - $227.6 $519,275 - $594,263	2,611 Added 6.25%	44,368 $9.98 Million
Q3 2021 Oct 27, 2021	BUY	$212.27 - $248.7 $316,494 - $370,811	1,491 Added 3.7%	41,757 $8.88 Million
Q2 2021 Aug 12, 2021	SELL	$233.58 - $259.14 $1.17 Million - $1.29 Million	-4,997 Reduced 11.04%	40,266 $9.82 Million
Q1 2021 May 14, 2021	BUY	$221.91 - $258.6 $993,712 - $1.16 Million	4,478 Added 10.98%	45,263 $11.3 Million
Q4 2020 Feb 10, 2021	BUY	$216.38 - $257.67 $1.05 Million - $1.25 Million	4,845 Added 13.48%	40,785 $9.38 Million
Q3 2020 Nov 13, 2020	SELL	$234.65 - $260.95 $13,375 - $14,874	-57 Reduced 0.16%	35,940 $9.13 Million
Q2 2020 Aug 24, 2020	BUY	$197.81 - $242.74 $199,194 - $244,439	1,007 Added 2.88%	35,997 $8.49 Million
Q1 2020 May 14, 2020	SELL	$182.24 - $241.7 $561,663 - $744,919	-3,082 Reduced 8.1%	34,990 $7.09 Million
Q4 2019 Feb 14, 2020	BUY	$189.21 - $243.2 $1.79 Million - $2.3 Million	9,442 Added 32.98%	38,072 $9.18 Million
Q3 2019 Oct 18, 2019	SELL	$174.11 - $208.62 $1.61 Million - $1.93 Million	-9,262 Reduced 24.44%	28,630 $5.54 Million
Q2 2019 Aug 01, 2019	BUY	$166.7 - $195.41 $623,458 - $730,833	3,740 Added 10.95%	37,892 $6.98 Million
Q1 2019 May 03, 2019	BUY	$180.87 - $203.88 $572,634 - $645,484	3,166 Added 10.22%	34,152 $6.49 Million
Q4 2018 Feb 11, 2019	BUY	$178.4 - $208.25 $1.01 Million - $1.18 Million	5,672 Added 22.41%	30,986 $6.03 Million
Q3 2018 Nov 14, 2018	BUY	$185.29 - $208.89 $43,728 - $49,298	236 Added 0.94%	25,314 $5.25 Million
Q2 2018 Aug 10, 2018	SELL	$166.05 - $186.51 $14,114 - $15,853	-85 Reduced 0.34%	25,078 $4.63 Million
Q1 2018 May 03, 2018	SELL	$169.43 - $198.0 $567,929 - $663,696	-3,352 Reduced 11.76%	25,163 $4.29 Million
Q4 2017 Feb 05, 2018	BUY	$168.79 - $188.59 $485,440 - $542,384	2,876 Added 11.22%	28,515 $4.96 Million
Q3 2017 Nov 08, 2017	BUY	$167.29 - $191.0 $590,366 - $674,039	3,529 Added 15.96%	25,639 $4.78 Million
Q2 2017 Aug 10, 2017	BUY	N/A	22,110	22,110 $3.81 Million

Others Institutions Holding AMGN

# of Institutions

3,082

Shares Held

417M

Call Options Held

7.24M

Put Options Held

6.26M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $172B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stephens Inc , based on Form 13F filings with the SEC.

News

Stay updated on Stephens Inc with notifications on news.

Account